Trial Profile
Ipilimumab 10 and 3 mg/kg in Canadian tertiary cancer centers.
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 01 Jul 2014
Price :
$35
*
At a glance
- Drugs Ipilimumab (Primary)
- Indications Malignant melanoma
- Focus Therapeutic Use
- 01 Jul 2014 New trial record
- 03 Jun 2014 Results presented at the 50th Annual Meeting of the American Society of Clinical Oncology.